Pearl Steinzor

Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.

Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.

Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.

AACR urges Congress to protect NIH/NCI funding amid a fight over a contested OMB grantmaking rule.

Mark Belkin, MD, explains why HFpEF goes undiagnosed, how MRA evidence should guide therapy, and what's next for AI-driven care.

PBM practices and split benefit coverage for oral vs IV chemotherapy drive high costs; a bill would close the gap for self-funded plans.

Ann Marie Navar, MD, PhD, on enlicitide's 60% LDL reduction, less than 50% ApoB lowering, fasting dosing rules, and how it compares with inclisiran.

Endometriosis was found to nearly double absenteeism and work-ability impairment, according to one study.

The ESC's 2026 heart failure guidelines overhaul HF classification, rename therapy categories, and add a new HFpEF recommendation.

A multicenter study found guideline-based grading underestimates tricuspid regurgitation severity and risk in ATTR-CM.

A new iPSC-derived platform from patients with endometriosis captures the disease's molecular and hormonal features in a human context.

The first study of its kind links nighttime light exposure to structural heart changes among over 11,000 adults followed for 3 years.

GLP-1 prescribing among children aged 8 to 11 years with obesity rose 310-fold from 2019 to 2026, but use remains rare and unevenly distributed by income.

Trejeeve Martyn, MD, shares why finerenone belongs on formulary, and how pharmacist-led access models can work in smaller health systems.

The combination therapy met the primary OS end point vs durvalumab alone as first-line ES-SCLC maintenance therapy in the phase 3 DeLLphi-305 trial.

Optum Health's Ken Cohen, MD, FACP, discusses findings from a recent study linking elective PVI to higher limb loss and costs.

Cleveland heart failure experts discuss the new HFpEF pathway, CKM screening gaps, and drug access barriers.

A random survival forest model trained on 850 patients outperformed the Mayo Clinic and National Amyloidosis Centre staging systems for ATTR-CM.

PVI for intermittent claudication was associated with more than double the rate of major adverse limb events and higher costs of care.

Late-breaking HELIOS-B subgroup data show mortality and CV benefits held regardless of baseline tafamidis use, per results at ESC Congress 2026.

A cohort study found lower breast cancer screening odds in the most redlined census tracts, independent of present-day social vulnerability.

A randomized crossover trial found dose-dependent driving impairment from THC edibles at blood concentrations below common per se limits.

A VESALIUS-CV analysis found a 20% reduction in all-cause death with evolocumab in patients without prior MI or stroke, emerging after 1.5 years.

Data show most older adults with newly diagnosed AML expect stable or improving physical function, while oncologists anticipate decline.

Part D plans are navigating intensifying pressure from GLP-1 therapies, which combine relatively high per-patient costs with a massive eligible population.

FUSION trial data published show FFRCT added to CCTA safely cut unnecessary catheterizations.

Tirzepatide is now approved to lower cardiovascular death, heart attack, or stroke risk in adults with type 2 diabetes.

County-level CRC mortality fell substantially since 2000, but some counties still had rates more than 13 times the Healthy People 2030 target in 2019.

AHIP's Jeanette Thornton details health care's prior authorization commitments as a 2027 real-time approval target approaches.

The phase 4 study will track serum transthyretin and other biomarkers in 50 adults with ATTR-CM switching from tafamidis to acoramidis over 6 months.